TGTX - Why Is Multiple Sclerosis-Focused TG Therapeutics Stock Trading Higher Today? | Benzinga
Wednesday, TG Therapeutics Inc (NASDAQ:TGTX) reported fourth-quarter 2023 revenues of $43.97 million, beating the consensus of $40.06 million.
Briumvi U.S. net product revenue reached $39.9 million for Q4 2023 and $88.8 million for the full year 2023.
Approximately 3,200 Briumvi prescriptions were received by TG Therapeutics since launch from around 640 healthcare providers at approximately 400 centers.
The company said the European Commission approval for Briumvi was received, leading to a partnership with Neuraxpharm for ex-U.S. commercialization.
Michael Weiss, Chairman and Chief Executive Officer, ...